Search
Now showing items 1-5 of 5
Proyecto arRISKu MUGAN: materiales para la reducción de los riesgos asociados al consumo de drogas
(Revista de la Asociación Española de Neuropsiquiatría, 2014)
[ES]Introducción: El Proyecto “arRISKu MUGAN” ha sido diseñado por las autoras en 2010, desde el Servicio de Psicología Aplicada de la UPV/EHU, con el apoyo de la Dirección de Drogodepen-dencias del Gobierno Vasco, la ...
Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients
(Sage, 2014-05-22)
Background: Natalizumab has shown its efficacy in reducing multiple sclerosis (MS) relapses and progression of disability; however, it has been associated with an increased risk of developing progressive multifocal ...
Transcriptomic profile reveals gender-specific molecular mechanisms driving multiple sclerosis progression
(Public Library Science, 2014-02-28)
Background: Although the most common clinical presentation of multiple sclerosis (MS) is the so called Relapsing-Remitting MS (RRMS), the molecular mechanisms responsible for its progression are currently unknown. To tackle ...
Buspirone anti-dyskinetic effect is correlated with temporal normalization of dysregulated striatal DRD1 signalling in L-DOPA-treated rats
(Elsevier, 2014-04)
Dopamine replacement with l-DOPA is the most effective therapy in Parkinson's disease. However, with chronic treatment, half of the patients develop an abnormal motor response including dyskinesias. The specific molecular ...
Sustained increase of PKA activity in the post-commissural putamen of dyskinetic monkeys
(Springer, 2014-04-05)
Levodopa-induced dyskinesias (LID) are a frequent complication of Parkinson's disease pharmacotherapy that causes significant disability and narrows the therapeutic window. Pharmacological management of LID is challenging ...